Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

WomanCart IPO Date, Review, Price, Allotment Details

By Jagat Joshi
October 25, 2023

WomanCart IPO Details: WomanCart IPO date is fixed, The IPO will open on October 16 and will close on October 18. WomanCart is an NSE SME IPO to raise ₹9.56 crores via IPO. The WomanCart IPO price band is fixed at ₹86 with a market lot of 1600 shares.

WomanCart is primarily a digital consumer-centric retail platform, providing a wide range of classic and emerging branded beauty and wellness products for skin care, body care, hair care, and fragrance for both men and women in the comfort of the home. They also sell lifestyle brands for make-up, imitation jewellery, and lingerie, They also run brick-and-mortar stores where customers can visit, make purchases, and interact with the brand.

They have specially sourced products to cater to everyday needs from skincare, makeup products, fragrance, hair styling products and tools, and a separate section for men and their grooming needs with shavers, trimmers, and beard care. They provide an easy shopping experience, good consumer service, high-quality products, and fashionable essentials from head to toe. Their product portfolio consists of approximately 10,000 SKUs from their brand along with various national & international brands.

WomanCart further launched our second store in Model Town, Delhi along with a Kiosk in Pacific Mall, Pitampura, Delhi. The Company also incorporated its 4 subsidiaries in the second half of FY 2022-23, which took over the running of online business listings on an online website. The fifth subsidiary M/s Varadda Overseas Private Limited shareholding was taken over from promoters during the same period.

Objects of the Issue:

To meet the expenses of Branding and Marketing.
To meet the expenses of App Development.
To meet the Working Capital requirements.
To meet the General Corporate Purposes.
To meet the Issue Expenses.

WomanCart IPO Review

May Apply

WomanCart IPO Date & Price Band Details

IPO Open:	October 16, 2023
IPO Close:	October 18, 2023
IPO Size:	Approx ₹9.56 Crores, 1,112,000 Equity Shares
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹86 Per Equity Share
IPO Listing on:	NSE SME
Retail Quota:	50% of the net offer
NII Quota:	50% of the net offer
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here

WomanCart IPO Market Lot

The WomanCart IPO minimum market lot is 1600 shares with a ₹137,600 application amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	1600	₹137,600
Retail Maximum	1	1600	₹137,600
S-HNI Minimum	2	3200	₹275,200

WomanCart IPO Dates

The WomanCart IPO date is October 16 and the IPO close date is October 18. The IPO allotment date is October 23 and the IPO might list on October 27.

IPO Open Date:	October 16, 2023
IPO Close Date:	October 18, 2023
Basis of Allotment:	October 23, 2023
Refunds:	October 25, 2023
Credit to Demat Account:	October 26, 2023
IPO Listing Date:	October 27, 2023

You can check IPO subscription status and IPO allotment status on their respective pages.

WomanCart IPO Form

How to apply WomanCart IPO? You can apply WomanCart IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the WomanCart IPO in the Invest section. The other option you can apply WomanCart IPO via IPO forms download via the NSE website. Check out the WomanCart forms – click NSE IPO Forms download, fill and submit in your bank or with your broker.

WomanCart Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹1.35	₹1.53	₹0.18
2022	₹4.26	₹4.04	₹0.21
2023	₹8.75	₹8.13	₹0.47
2023 5M	₹7.65	₹6.91	₹0.54

WomanCart IPO Valuation – FY2023

Check WomanCart IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹1.70 per Equity Share
Price/Earning P/E Ratio:	NA
Return on Net Worth (RoNW):	15.11%
Net Asset Value (NAV):	₹28.08 per Equity Share

Peer Group

FSN E-Commerce Ventures Ltd (Nykaa)

Company Promoters

Mrs. Veena Pahwa

WomanCart IPO Registrar

Maashitla Securities Private Limited
Phone: +91-11-45121795-96
Email: ipo@maashitla.com
Website: https://maashitla.com/

WomanCart IPO Allotment Status

Check WomanCart IPO allotment status on Maashitla Securities website URL. Click Here

WomanCart IPO Lead Managers aka Merchant Bankers

Narnolia Financial Services Ltd

Company Address

WomanCart Limited
House No. 57,
3rd Floor, Block F-14
Model Town, New Delhi- 110009
Phone: +919205577453
Email: secretarial@WomanCart.com
Website: https://www.womancart.in/

WomanCart IPO FAQs

What is WomanCart IPO?

WomanCart IPO is an NSE SME IPO. They are going to raise ₹9.56 Crores via IPO. The issue is priced at ₹86 per equity share. The IPO is to be listed on NSE.

When WomanCart IPO will open?

The IPO is to open on October 16, 2023 for NII, and Retail Investors.

What is WomanCart IPO Investors Portion?

The investors’ portion for QIB is [.]%, NII is 50%, and Retail is 50%.

How to Apply the WomanCart IPO?

You can apply WomanCart IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the WomanCart IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “WomanCart”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the WomanCart IPO through Upstox?

Log in to Upstox Application with your credentials. Select the IPO. You will see the IPO Name “WomanCart”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the WomanCart IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “WomanCart”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is WomanCart IPO Size?

WomanCart IPO size is ₹9.56 crores.

What is WomanCart IPO Price Band?

WomanCart IPO Price Band is ₹86 per equity share.

What is WomanCart IPO Minimum and Maximum Lot Size?

The IPO bid is 1600 shares with ₹137,600.

What is WomanCart IPO Allotment Date?

WomanCart IPO allotment date is October 23, 2023.

What is WomanCart IPO Listing Date?

WomanCart IPO listing date is October 27, 2023. The IPO to list on NSE SME.

Note: The WomanCart IPO details are announced officially. The IPO grey market premium (WomanCart IPO Premium) is updated on the respective page. You can check our IPO grey market page for daily updates.)

Follow IPO Watch for the upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.

Jagat Joshi

Add IPOWatch to your Google News feed.

3 Responses

Ravish agrawal says:

October 12, 2023 at 7:38 PM

A company having revenue of less than 9 crores is looking to raise more than 9 crores, that too at a premium valuation !!!!
D.m si ngh says:

October 12, 2023 at 11:19 AM

Lot size could be smaller so as small retailers can also take part in investment
1. IPOWatch Team says:
  
  October 12, 2023 at 12:01 PM
  
  Hello Visitor,
  
  The SME IPO Lot Size always on a higher side so that it can meet the investment of above 1 Lakh.